Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration.

Joseph M ConeyRyan ZubrickySamriddhi Buxy SinhaNina SonbolianLujia ZhouThomas P HullShawn A LewisDavid G MillerMichael A NovakScott D PendergastHang PhamSean M PlattLlewelyn J RaoJerome P SchartmanLawrence J SingermanRichard DonkorMargaret FinkJasmyne McCoyHelene Karcher

Published in: International journal of retina and vitreous (2023)

This real-world study demonstrates that injection intervals may be significantly extended with maintained vision and reduced CMT in nAMD eyes switching to brolucizumab therapy from other anti-VEGFs.

Keyphrases

age related macular degeneration
optical coherence tomography
ultrasound guided
stem cells
type diabetes
adipose tissue
metabolic syndrome
mesenchymal stem cells
cataract surgery
bone marrow
endothelial cells
vascular endothelial growth factor
smoking cessation